1201915-85-6 Usage
Description
(S)-tert-butyl 2-(5-phenyl-1,3,4-oxadiazol-2-yl)pyrrolidine-1-carboxylate is a complex chemical compound that features a tert-butyl group, a pyrrolidine ring, and a phenyl-oxadiazolyl moiety. It is a member of the pyrrolidine carboxylate class and is recognized for its potential biological activities. (S)-tert-butyl 2-(5-phenyl-1,3,4-oxadiazol-2-yl)pyrrolidine-1-carboxylate is particularly valuable in the field of pharmaceutical research and development, where it serves as a building block for synthesizing a variety of biologically active molecules. Its distinctive structural and chemical properties position it as a significant asset in medicinal chemistry, aiding in the discovery of novel drugs and therapeutic agents.
Uses
Used in Pharmaceutical Research and Development:
(S)-tert-butyl 2-(5-phenyl-1,3,4-oxadiazol-2-yl)pyrrolidine-1-carboxylate is used as a building block for the synthesis of biologically active molecules due to its complex structure and potential biological activities. It plays a crucial role in the development of new drugs and therapeutic agents, contributing to advancements in medicinal chemistry.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (S)-tert-butyl 2-(5-phenyl-1,3,4-oxadiazol-2-yl)pyrrolidine-1-carboxylate is utilized as a valuable tool for the discovery of novel drugs. Its unique properties and structural features enable researchers to explore new avenues in drug design and therapeutic intervention strategies.
Used in the Synthesis of Biologically Active Molecules:
(S)-tert-butyl 2-(5-phenyl-1,3,4-oxadiazol-2-yl)pyrrolidine-1-carboxylate is employed as a key component in the synthesis of various biologically active molecules. Its incorporation into these molecules can potentially enhance their efficacy, selectivity, and overall therapeutic potential, making it an indispensable compound in the development of innovative pharmaceuticals.
Check Digit Verification of cas no
The CAS Registry Mumber 1201915-85-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,1,9,1 and 5 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1201915-85:
(9*1)+(8*2)+(7*0)+(6*1)+(5*9)+(4*1)+(3*5)+(2*8)+(1*5)=116
116 % 10 = 6
So 1201915-85-6 is a valid CAS Registry Number.
1201915-85-6Relevant articles and documents
From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs
Bolli, Martin H.,Boss, Christoph,Brotschi, Christine,Gatfield, John,Heidmann, Bibia,Jenck, Francois,Roch, Catherine,Sifferlen, Thierry,Treiber, Alexander,Williams, Jodi T.
, (2020/01/25)
The orexin system is responsible for regulating the sleep-wake cycle. Suvorexant, a dual orexin receptor antagonist (DORA) is approved by the FDA for the treatment of insomnia disorders. Herein, we report the optimization efforts toward a DORA, where our starting point was (5-methoxy-4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}methanone (6), a compound which emerged from our in-house research program. Compound 6 was shown to be a potent, brain-penetrating DORA with in vivo efficacy similar to suvorexant in rats. However, shortcomings from low metabolic stability, high plasma protein binding (PPB), low brain free fraction (fu brain), and low aqueous solubility, were identified and hence, compound 6 was not an ideal candidate for further development. Our optimization efforts addressing the above-mentioned shortcomings resulted in the identification of (4-chloro-2-[1,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1,2,4]triazol-3-yl]-pyrrolidin-1-yl}l-methanone (42), a DORA with improved in vivo efficacy compared to 6.
The design of potent and selective inhibitors of DPP-4: Optimization of ADME properties by amide replacements
Nordhoff, Sonja,Bulat, Stephan,Cerezo-Galvez, Silvia,Hill, Oliver,Hoffmann-Enger, Barbara,Lopez-Canet, Meritxell,Rosenbaum, Claudia,Rummey, Christian,Thiemann, Meinolf,Matassa, Victor G.,Edwards, Paul J.,Feurer, Achim
scheme or table, p. 6340 - 6345 (2010/06/11)
For a series of β-homophenylalanine based inhibitors of dipeptidyl peptidase IV ADME properties were improved by the incorporation of amide replacements. These efforts led to a novel series of potent and selective inhibitors of DPP-4 that exhibit an attractive pharmacokinetic profile and show excellent efficacy in an animal model of diabetes.
